FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3107716360> ?p ?o ?g. }

• W3107716360 endingPage "411" @default.
• W3107716360 startingPage "404" @default.
• W3107716360 abstract "•Large lesion dissemination measured by high SDmax was a strong prognosticator of shorter PFS and OS in DLBCL patients.•SDmax results in an accurate risk stratification at baseline, even in advanced Ann Arbor stage patients.•SDmax and MTV are independent prognosticators and identified a high-risk group among DLBCL patients responding to R-CHOP.•SDmax combined with MTV seems superior to IPI or NCCN-IPI stratifications and promises to guide therapeutic strategy. BackgroundWe analyzed the prognostic value of a new baseline positron emission tomography (PET) parameter reflecting the spread of the disease, the largest distance between two lesions (Dmax). We tested its complementarity to metabolic tumor volume (MTV) in a large cohort of diffuse large B-cell lymphoma (DLBCL) patients from the REMARC trial (NCT01122472).Patients and methodsMTVs were defined using the 41% maximum standardized uptake value threshold. From the three-dimensional coordinates, the centroid of each lesion was automatically obtained and considered as the lesion location. The distances between all pairs were calculated. Dmax was obtained for each patient and normalized with the body surface area [standardized Dmax (SDmax)].ResultsFrom the REMARC trial, 290 patients aged 60-80 years were included: 91% had an advanced stage and 71% International Prognostic Index (IPI) ≥3. High versus low SDmax significantly impacted progression-free survival (PFS) (P < 0.0001) and overall survival (OS) (P = 0.0027). Patients with SDmax > 0.32 m−1 (n = 82) had a 4-year PFS and OS of 46% and 71%, respectively, against 77% and 87%, respectively, for patients with low SDmax. High SDmax and high MTV were independent prognostic factors of PFS (P = 0.0001 and P = 0.0010, respectively) and OS (P = 0.0028 and P = 0.0004, respectively). Combining MTV and SDmax yielded three risk groups with no (n = 109), one (n = 122) or two (n = 59) factors (P < 0.0001 for both PFS and OS). The 4-year PFS were 90%, 63%, 41%, respectively, and the 4-year OS were 95%, 79%, 66%, respectively. In addition, patients with at least two of the three factors including high SDmax, high MTV, Eastern Cooperative Oncology Group (ECOG) ≥2 had a higher number of central nervous system relapse (P = 0.017).ConclusionsSDmax is a simple feature that captures lymphoma dissemination, independent from MTV. These two PET metrics, SDmax and MTV, are complementary to characterize the disease, reflecting the tumor burden and its spread. This score appeared promising for DLBCL baseline risk stratification. We analyzed the prognostic value of a new baseline positron emission tomography (PET) parameter reflecting the spread of the disease, the largest distance between two lesions (Dmax). We tested its complementarity to metabolic tumor volume (MTV) in a large cohort of diffuse large B-cell lymphoma (DLBCL) patients from the REMARC trial (NCT01122472). MTVs were defined using the 41% maximum standardized uptake value threshold. From the three-dimensional coordinates, the centroid of each lesion was automatically obtained and considered as the lesion location. The distances between all pairs were calculated. Dmax was obtained for each patient and normalized with the body surface area [standardized Dmax (SDmax)]. From the REMARC trial, 290 patients aged 60-80 years were included: 91% had an advanced stage and 71% International Prognostic Index (IPI) ≥3. High versus low SDmax significantly impacted progression-free survival (PFS) (P < 0.0001) and overall survival (OS) (P = 0.0027). Patients with SDmax > 0.32 m−1 (n = 82) had a 4-year PFS and OS of 46% and 71%, respectively, against 77% and 87%, respectively, for patients with low SDmax. High SDmax and high MTV were independent prognostic factors of PFS (P = 0.0001 and P = 0.0010, respectively) and OS (P = 0.0028 and P = 0.0004, respectively). Combining MTV and SDmax yielded three risk groups with no (n = 109), one (n = 122) or two (n = 59) factors (P < 0.0001 for both PFS and OS). The 4-year PFS were 90%, 63%, 41%, respectively, and the 4-year OS were 95%, 79%, 66%, respectively. In addition, patients with at least two of the three factors including high SDmax, high MTV, Eastern Cooperative Oncology Group (ECOG) ≥2 had a higher number of central nervous system relapse (P = 0.017). SDmax is a simple feature that captures lymphoma dissemination, independent from MTV. These two PET metrics, SDmax and MTV, are complementary to characterize the disease, reflecting the tumor burden and its spread. This score appeared promising for DLBCL baseline risk stratification." @default.
• W3107716360 created "2020-12-07" @default.
• W3107716360 creator A5003436735 @default.
• W3107716360 creator A5014639728 @default.
• W3107716360 creator A5017919002 @default.
• W3107716360 creator A5025204567 @default.
• W3107716360 creator A5033073385 @default.
• W3107716360 creator A5055439790 @default.
• W3107716360 creator A5062305482 @default.
• W3107716360 creator A5071620424 @default.
• W3107716360 creator A5079749862 @default.
• W3107716360 creator A5083883351 @default.
• W3107716360 date "2021-03-01" @default.
• W3107716360 modified "2023-10-18" @default.
• W3107716360 title "Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†" @default.
• W3107716360 cites W1972232210 @default.
• W3107716360 cites W2018071905 @default.
• W3107716360 cites W2063691874 @default.
• W3107716360 cites W2072351874 @default.
• W3107716360 cites W2133201432 @default.
• W3107716360 cites W2275941472 @default.
• W3107716360 cites W2290716155 @default.
• W3107716360 cites W2291210741 @default.
• W3107716360 cites W2310716991 @default.
• W3107716360 cites W2472919944 @default.
• W3107716360 cites W2507512417 @default.
• W3107716360 cites W2605767476 @default.
• W3107716360 cites W2615482883 @default.
• W3107716360 cites W2784752532 @default.
• W3107716360 cites W2787594587 @default.
• W3107716360 cites W2797584152 @default.
• W3107716360 cites W2799976003 @default.
• W3107716360 cites W2801726309 @default.
• W3107716360 cites W2801763724 @default.
• W3107716360 cites W2809848353 @default.
• W3107716360 cites W2927995861 @default.
• W3107716360 cites W2949514247 @default.
• W3107716360 cites W2989546915 @default.
• W3107716360 cites W3002263815 @default.
• W3107716360 cites W3011375925 @default.
• W3107716360 cites W3015964023 @default.
• W3107716360 cites W4205736005 @default.
• W3107716360 doi "https://doi.org/10.1016/j.annonc.2020.11.019" @default.
• W3107716360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33278600" @default.
• W3107716360 hasPublicationYear "2021" @default.
• W3107716360 type Work @default.
• W3107716360 sameAs 3107716360 @default.
• W3107716360 citedByCount "58" @default.
• W3107716360 countsByYear W31077163602020 @default.
• W3107716360 countsByYear W31077163602021 @default.
• W3107716360 countsByYear W31077163602022 @default.
• W3107716360 countsByYear W31077163602023 @default.
• W3107716360 crossrefType "journal-article" @default.
• W3107716360 hasAuthorship W3107716360A5003436735 @default.
• W3107716360 hasAuthorship W3107716360A5014639728 @default.
• W3107716360 hasAuthorship W3107716360A5017919002 @default.
• W3107716360 hasAuthorship W3107716360A5025204567 @default.
• W3107716360 hasAuthorship W3107716360A5033073385 @default.
• W3107716360 hasAuthorship W3107716360A5055439790 @default.
• W3107716360 hasAuthorship W3107716360A5062305482 @default.
• W3107716360 hasAuthorship W3107716360A5071620424 @default.
• W3107716360 hasAuthorship W3107716360A5079749862 @default.
• W3107716360 hasAuthorship W3107716360A5083883351 @default.
• W3107716360 hasBestOaLocation W31077163601 @default.
• W3107716360 hasConcept C126322002 @default.
• W3107716360 hasConcept C142724271 @default.
• W3107716360 hasConcept C143998085 @default.
• W3107716360 hasConcept C146357865 @default.
• W3107716360 hasConcept C151730666 @default.
• W3107716360 hasConcept C199374082 @default.
• W3107716360 hasConcept C2775842073 @default.
• W3107716360 hasConcept C2776694085 @default.
• W3107716360 hasConcept C2778476033 @default.
• W3107716360 hasConcept C2778559949 @default.
• W3107716360 hasConcept C2779338263 @default.
• W3107716360 hasConcept C2780653079 @default.
• W3107716360 hasConcept C2780739268 @default.
• W3107716360 hasConcept C2781156865 @default.
• W3107716360 hasConcept C2781214270 @default.
• W3107716360 hasConcept C2989005 @default.
• W3107716360 hasConcept C71924100 @default.
• W3107716360 hasConcept C86803240 @default.
• W3107716360 hasConceptScore W3107716360C126322002 @default.
• W3107716360 hasConceptScore W3107716360C142724271 @default.
• W3107716360 hasConceptScore W3107716360C143998085 @default.
• W3107716360 hasConceptScore W3107716360C146357865 @default.
• W3107716360 hasConceptScore W3107716360C151730666 @default.
• W3107716360 hasConceptScore W3107716360C199374082 @default.
• W3107716360 hasConceptScore W3107716360C2775842073 @default.
• W3107716360 hasConceptScore W3107716360C2776694085 @default.
• W3107716360 hasConceptScore W3107716360C2778476033 @default.
• W3107716360 hasConceptScore W3107716360C2778559949 @default.
• W3107716360 hasConceptScore W3107716360C2779338263 @default.
• W3107716360 hasConceptScore W3107716360C2780653079 @default.
• W3107716360 hasConceptScore W3107716360C2780739268 @default.
• W3107716360 hasConceptScore W3107716360C2781156865 @default.
• W3107716360 hasConceptScore W3107716360C2781214270 @default.
• W3107716360 hasConceptScore W3107716360C2989005 @default.

• next